Free Trial
NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

Olema Pharmaceuticals logo
$10.74 -0.01 (-0.09%)
Closing price 10/14/2025 04:00 PM Eastern
Extended Trading
$10.56 -0.18 (-1.68%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Advanced

Key Stats

Today's Range
$10.41
$11.06
50-Day Range
$4.57
$11.14
52-Week Range
$2.86
$13.51
Volume
1.22 million shs
Average Volume
1.17 million shs
Market Capitalization
$737.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.33
Consensus Rating
Moderate Buy

Company Overview

Olema Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

OLMA MarketRank™: 

Olema Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 567th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Olema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Olema Pharmaceuticals has a consensus price target of $23.33, representing about 117.3% upside from its current price of $10.74.

  • Amount of Analyst Coverage

    Olema Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Olema Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.33) to ($2.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Olema Pharmaceuticals is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Olema Pharmaceuticals is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Olema Pharmaceuticals has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Olema Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.01% of the outstanding shares of Olema Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Olema Pharmaceuticals has recently decreased by 2.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    Olema Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Olema Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.01% of the outstanding shares of Olema Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Olema Pharmaceuticals has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Olema Pharmaceuticals has recently decreased by 2.02%, indicating that investor sentiment is improving.
  • News Sentiment

    Olema Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 7 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $204,841.00 in company stock.

  • Percentage Held by Insiders

    16.36% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Olema Pharmaceuticals' insider trading history.
Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OLMA Stock News Headlines

4 Stocks to Watch as Markets Enter Unchartered Territory
FREE Report: 4 “America First” Stocks Poised to Soar Under Trump’s New Tariffs President Trump’s second term is officially underway—and during his first 100 days are already delivering bold moves on tariffs, energy, defense, and trade.tc pixel
See More Headlines

OLMA Stock Analysis - Frequently Asked Questions

Olema Pharmaceuticals' stock was trading at $5.83 on January 1st, 2025. Since then, OLMA shares have increased by 84.2% and is now trading at $10.74.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) announced its quarterly earnings data on Monday, August, 11th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.08.

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO.

Top institutional shareholders of Olema Pharmaceuticals include Voya Investment Management LLC (0.02%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen and Naseem Zojwalla.
View institutional ownership trends
.

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
8/11/2025
Today
10/15/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OLMA
CIK
1750284
Fax
N/A
Employees
70
Year Founded
2007

Price Target and Rating

High Price Target
$30.00
Low Price Target
$18.00
Potential Upside/Downside
+117.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$129.47 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.58%
Return on Assets
-38.65%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
11.09
Quick Ratio
11.09

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.14 per share
Price / Book
1.50

Miscellaneous

Outstanding Shares
68,630,000
Free Float
57,405,000
Market Cap
$737.09 million
Optionable
Optionable
Beta
2.08

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:OLMA) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners